Trial
NCT06227897
Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
—
Condition
Lung Cancer
Intervention
Aumolertinib
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-10